title: [High level of lipoprotein (a) as a predictor of poor long-term prognosis after coronary artery bypass surgery].
abstract: Study aim was to investigate the association of lipoprotein (a) [Lp(a)] level with the development of cardiovascular complications in long-term follow-up period after coronary artery bypass grafting (CABG). Patients with chronic ischemic heart disease (IHD) (n = 361, 88% men, mean age 55 +/- 9 years) who had had CABG were included in the study. Before surgery we assessed presence of classical risk factors, left ventricular ejection fraction, concentrations of lipids and Lp(a) in blood serum. During follow-up (from 1 to 140, mean 66 +/- 34 months) we registered cardiac deaths, nonfatal myocardial infarctions (MI), strokes, repeat procedures of revascularization, and hospitalizations due to relapse or progression of angina pectoris. Information on prognosis was obtained from 263 patients. In 109 of them we registered 142 serious events including cardiac death n = 20 (14%), nonfatal MI n = 14 (10%), myocardial revascularization (n = 35), 29 (20%) with stenting), repeat CABG n = 6 (4%), hospitalization due to angina pectoris n = 53 (37%), stroke n = 4 (3%), noncardiac outcome n = 16 (10%). In subjects with hyperlipidemia (a) [HLp(a) - Lp(a) > 30 mg/l] survival after CABG was lower (log rank p < 0.001): 11 of 93 (11.3%) and 9 of 170 (5.2%) patients died among those with Lp(a) > 30 and < 30 mg/I, respectively. Relative risk (RR) of any cardiovascular complication was 3.24 (95% confidence interval [CI] 2.18 to 4.83, p < 0.001), of death - 2.89 (95% CI 1.31 to 6.35, p < 0.01), and of MI A 1.01 (95% CI 1.00 to 1.02; p = 0.02). RR of development of MI and cardiac death in patients with HLp(a) in 5 years was 2.61 (95% CI 1.11 to 5.74; p = 0.02), in 10 years - 2.95 (95% CI 1.50 to 5.79; p < 0.001). In patients with chronic IHD high level of Lp(a) can serve as independent predictor of unfavorable events including death and nonfatal MI during 10 years after CABG.
authors.forename: M V
authors.initials: MV
authors.lastname: Ezhov
authors.forename: M C
authors.initials: MC
authors.lastname: Safarova
authors.forename: O I
authors.initials: OI
authors.lastname: Afanas'eva
authors.forename: L N
authors.initials: LN
authors.lastname: Il'ina
authors.forename: A A
authors.initials: AA
authors.lastname: Liakishev
authors.forename: S N
authors.initials: SN
authors.lastname: Pokrovskiĭ
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003643:Death; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism / Q000503:physiopathology; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D011379:Prognosis; D012086:Reoperation; D012307:Risk Factors
chemical_list: D017270:Lipoprotein(a)